CAR13
MOLECULAR TARGETcarbonic anhydrase 13
CAR13 (carbonic anhydrase 13) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CAR13
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Chlorthalidone | 1.61 | 4 |
| 2 | Indapamide | 1.61 | 4 |
| 3 | Furosemide | 1.39 | 3 |
| 4 | Bumetanide | 1.10 | 2 |
| 5 | Histamine | 1.10 | 2 |
| 6 | Mafenide | 1.10 | 2 |
| 7 | Metolazone | 1.10 | 2 |
| 8 | stx64 | 1.10 | 2 |
| 9 | Sulfanilamide | 1.10 | 2 |
| 10 | Zonisamide | 1.10 | 2 |
| 11 | Histidine | 0.69 | 1 |
| 12 | Quercetin | 0.69 | 1 |
About CAR13 as a Drug Target
CAR13 (carbonic anhydrase 13) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented CAR13 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CAR13 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.